Clinical Trial

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with serplulimab as first-line treatment in patients with extensive-stage small cell lung cancer.
Trial Details
NCT Number NCT07739758
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Collaborators: Shanghai Henlius Biotech
Conditions SCLC, Extensive Stage
Enrollment 442 participants
Start Date 2026-08
Primary Completion 2029-06 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-31